key inclusion criteria: 1. is healthy or has chronic medical condition(s) that is stable and well controlled as per the opinion of the investigator and is not likely to require medical intervention through the end of study 2. stable medication for co-morbid condition(s) for at least 6 months prior to screening 3. willing and able to comply with study visits and study-related procedures, including compliance with site precautionary requirements related to sars-cov-2 infection and transmission key

key inclusion criteria: 1. is healthy or has chronic medical condition(s) that is stable and well controlled as per the opinion of the investigator and is not likely to require medical intervention through the end of study 2. stable medication for co-morbid condition(s) for at least 6 months prior to screening 3. willing and able to comply with study visits and study-related procedures, including compliance with site precautionary requirements related to sars-cov-2 infection and transmission key

key inclusion criteria: is healthy or has chronic medical condition(s) that is stable and well controlled as per the opinion of the investigator and is not likely to require medical intervention through the end of study stable medication for co-morbid condition(s) for at least 6 months prior to screening willing and able to comply with study visits and study-related procedures, including compliance with site precautionary requirements related to sars-cov-2 infection and transmission key

key inclusion criteria: is healthy or has chronic medical condition(s) that is stable and well controlled as per the opinion of the investigator and is not likely to require medical intervention through the end of study stable medication for co-morbid condition(s) for at least 6 months prior to screening willing and able to comply with study visits and study-related procedures, including compliance with site precautionary requirements related to sars-cov-2 infection and transmission key

key inclusion criteria: 1. is healthy or has chronic medical condition(s) that is stable and well controlled as per the opinion of the investigator and is not likely to require medical intervention through the end of study 2. stable medication for co-morbid condition(s) for at least 6 months prior to screening 3. willing and able to comply with study visits and study-related procedures, including compliance with site precautionary requirements related to sars-cov-2 infection and transmission key

key inclusion criteria: 1. is healthy or has chronic medical condition(s) that is stable and well controlled as per the opinion of the investigator and is not likely to require medical intervention through the end of study 2. stable medication for co-morbid condition(s) for at least 6 months prior to screening 3. willing and able to comply with study visits and study-related procedures, including compliance with site precautionary requirements related to sars-cov-2 infection and transmission key